Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL(pro) Inhibitors

The 3C-like protease (3CL(pro)) of SARS-CoV-2 is considered an excellent target for COVID-19 antiviral drug development because it is essential for viral replication and has a cleavage specificity distinct from human proteases. However, drug development for 3CL(pro) has been hindered by a lack of ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawson, Jonathan M. O., Duchon, Alice, Nikolaitchik, Olga A., Pathak, Vinay K., Hu, Wei-Shau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911889/
https://www.ncbi.nlm.nih.gov/pubmed/33498923
http://dx.doi.org/10.3390/v13020173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911889/
https://www.ncbi.nlm.nih.gov/pubmed/33498923
http://dx.doi.org/10.3390/v13020173

Ejemplares similares